# Concept: Capitalised research and development expense for approval for new drug 

## Bilingual Labels
- **EN**: Capitalised research and development expense for approval for new drug 
- **KO**: 판매승인 시점의 자산화된 연구개발비, 바이오 제약

- **ID**: dart:CapitalisedResearchAndDevelopmentExpenseForApprovalForNewDrug

## Reported Numerical Facts

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 40,922,218,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 39,393,606,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 40,922,218,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 39,393,606,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 670,852,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 760,112,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 670,852,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 760,112,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 5,142,604,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 5,125,632,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 2,553,707,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 2,536,837,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 3,558,210,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 4,443,716,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 1,230,856,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 1,250,067,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2025-03-31**
  - **Value**: 5,159,575,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 118,119,685,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 116,707,001,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 118,119,685,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 116,707,001,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 8,357,252,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 21,990,629,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 8,357,252,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 21,990,629,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 23,213,225,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 24,755,848,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 23,213,225,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 24,755,848,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 7,372,962,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 6,574,802,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 7,372,962,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 6,574,802,000 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 207,357,008,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 219,751,346,000 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 202,440,757,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 213,968,902,000 (decimals: -3)

## Accounting Standard References
- **Standard**: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan

---
*Source Document: entity00413046_2025-03-31.xbrl*
## Embeddable Text (for FAISS)
```text
Concept: Capitalised research and development expense for approval for new drug 
Bilingual Labels
 EN: Capitalised research and development expense for approval for new drug 
 KO: 판매승인 시점의 자산화된 연구개발비, 바이오 제약
 ID: dart:CapitalisedResearchAndDevelopmentExpenseForApprovalForNewDrug
Reported Numerical Facts
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 40,922,218,000 (decimals: 3)
 Period: 20250331
   Value: 39,393,606,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 40,922,218,000 (decimals: 3)
 Period: 20250331
   Value: 39,393,606,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 670,852,000 (decimals: 3)
 Period: 20250331
   Value: 760,112,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 670,852,000 (decimals: 3)
 Period: 20250331
   Value: 760,112,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 5,142,604,000 (decimals: 3)
 Period: 20250331
   Value: 5,125,632,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 2,553,707,000 (decimals: 3)
 Period: 20250331
   Value: 2,536,837,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 3,558,210,000 (decimals: 3)
 Period: 20250331
   Value: 4,443,716,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 1,230,856,000 (decimals: 3)
 Period: 20250331
   Value: 1,250,067,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20250331
   Value: 5,159,575,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 118,119,685,000 (decimals: 3)
 Period: 20250331
   Value: 116,707,001,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 118,119,685,000 (decimals: 3)
 Period: 20250331
   Value: 116,707,001,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 8,357,252,000 (decimals: 3)
 Period: 20250331
   Value: 21,990,629,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 8,357,252,000 (decimals: 3)
 Period: 20250331
   Value: 21,990,629,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 23,213,225,000 (decimals: 3)
 Period: 20250331
   Value: 24,755,848,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 23,213,225,000 (decimals: 3)
 Period: 20250331
   Value: 24,755,848,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 7,372,962,000 (decimals: 3)
 Period: 20250331
   Value: 6,574,802,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 7,372,962,000 (decimals: 3)
 Period: 20250331
   Value: 6,574,802,000 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 207,357,008,000 (decimals: 3)
 Period: 20250331
   Value: 219,751,346,000 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 202,440,757,000 (decimals: 3)
 Period: 20250331
   Value: 213,968,902,000 (decimals: 3)
Accounting Standard References
 Standard: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan
Source Document: entity00413046_20250331.xbrl
```